Slow to change and risk averse, the pharmaceutical industry lags behind many industries in manufacturing efficiency. While many other manufacturing industries have moved to, or are in the process of adopting a continuous manufacturing paradigm, the pharmaceutical industry is just beginning to explore the possibilities of moving from traditional batch-based manufacturing processes to a more continuous, and some might argue efficient process.
Where is the industry now in its journey to a continuous process? Is it even feasible given the industry’s historically slow adoption of new technology? What are the regulatory ramifications of moving to a continuous process, and, what is the FDA doing to make the journey easier?
To explore these topics and to take a deeper look at the issues surrounding continuous processing, American Pharmaceutical Review is interviewing some of the industry’s leading thought leaders on the subject. Our experts come from all facets of the industry: regulatory, manufacturing, and consulting; and each have their own unique take on the topic.